Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jun 15, 2006 (Vol. 26, No. 12)

This Week in Science Podcasts

  • Entertaining
  • Needs a different format
If there is a single word that historians will use to refer to the first decade of the 21st century, it may well turn out to be podcast. Let’s hope it isn’t blogging. Podcasts are the hottest thing in communications since the Internet itself. With podcasts making inroads with traditional publishing interests (GEN offers a podcast, for example), there are a lot to keep track of. Enter This Week in Science Podcasts, which aims to serve the scientific segment of this new communication. While the site itself scores major points for broad coverage, even beyond science, its organization leaves a bit to be desired. The science broadcasts are mp3s, involving a couple of talking heads and the format is simply conversational—sort of a %Tonight Show%. While the topics are interesting, the coverage could be better, much better.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »